Article Index - HemaSphere - Wiley Online Library

All HemaSphere Articles

Filters

81-100 of 166 results

Relevance

Export Citation(s)Download PDF(s)

Perspective
Open Access

oa

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications
Aaron T. Gerds, Prithviraj Bose, Gabriela S. Hobbs, Andrew T. Kuykendall, Lynn M. Neilson, Jinlin Song, Barbara Klencke, Claire N. Harrison,

First published: 30 September 2022
Article
Open Access

oa

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Anita Badbaran, Christina Rautenberg, Victoria Panagiota, Christine Wolschke, Felicitas Thol, Bruno Cassinat, Marie Robin, Michael Heuser, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger,

First published: 30 September 2022
Letter
Open Access

oa

UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia
Carmelo Gurnari, Peter Mannion, Ishani Pandit, Simona Pagliuca, Maria Teresa Voso, Jaroslaw P. Maciejewski, Valeria Visconte, Heesun J. Rogers,

First published: 27 September 2022
Letter
Open Access

oa

U2AF1^S34/Q157 Variants Detected in cis Arise Sequentially in an MDS Patient With Serial Sequencing Spanning 18 Years
Christina K. Ferrone, Amy J. M. McNaughton, Felicia Vincelli, Philip Zuzarte, David Lee, Harriet E. Feilotter, Michael J. Rauh,

First published: 22 September 2022
Letter
Open Access

oa

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany
Krischan Braitsch, Laura K. Schmalbrock, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Judith S. Hecker, Mareike Verbeek, Jörg Westermann, Lars Bullinger, Ulrich Keller, Florian Bassermann, Jan Krönke, Katharina S. Götze, Kathrin Rieger,

First published: 09 August 2022
Letter
Open Access

oa

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
Claire Harrison, Florian H. Heidel, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Amjad Hayat, Francesco Passamonti, Eibhlin Conneally, Thomas Kindler, Bruno Martino, Daniel B. Lipka, Tommaso Stefanelli, Pantelia Roussou, Davide Germano, Jacqueline Ewan, Vincent Ribrag,

First published: 02 August 2022
Letter
Open Access

oa

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
Somayya Noori, Marina Zajec, Henk Russcher, Andrei N. Tintu, Annemiek Broijl, Joannes F. M. Jacobs, Theo M. Luider, Yolanda B. de Rijke, Martijn M. vanDuijn,

First published: 02 August 2022
Letter
Open Access

oa

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
Axel Rüfer, Hubert Angermann, Rudolf Benz, Nicolas Bonadies, Antonello Calderoni, Nathan Cantoni, Anna Efthymiou, Robert Escher, Geneviève Favre, Dorothea Friess, Andreas Gschwend, Andreas Himmelmann, Andreas Holbro, Peter Keller, Eirini Kouroupi, Thomas Lehmann, Nikolaus Pedarnig, Véronique Rigamonti, Kaveh Samii, Adrian Schmidt, Hans-Peter Schäfer, Roland Sperb, Georg Stüssi, Annette Winkler, Reinhard Zenhäusern, Jeroen S. Goede, SLIM-Registry Investigators,

First published: 17 June 2022
Editorial
Open Access

oa

Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?
Jannik Stemler, Oliver A. Cornely,

First published: 17 June 2022
HemaPolicy
Open Access

oa

Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
Isabel Dombrink, Bart R. Lubbers, Loredana Simulescu, Robin Doeswijk, Olga Tkachenko, Elisabeth Dequeker, Alan G. Fraser, Jacques J. M. van Dongen, Christa Cobbaert, Monika Brüggemann, Elizabeth Macintyre,

First published: 20 May 2022
Letter
Open Access

oa

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew Kuykendall, Casey L. O'Connell, Jamile M. Shammo, Angela Fleischman, Ruben Mesa, Abdulraheem Yacoub, Ronald Hoffman, Erin Moshier, Nicole Zubizarreta, John Mascarenhas,

First published: 11 May 2022
Article
Open Access

oa

The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA
Miriam Rehberger, Jonas A. Schäfer, Anna-Maria Krampitz, Anne Catherine Bretz, Lukas Jost, Torsten Haferlach, Thorsten Stiewe, Andreas Neubauer,

First published: 26 April 2022
Article
Open Access

oa

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes
Amalie Bach Nielsen, Jakob Werner Hansen, Andreas Due Ørskov, Konstantinos Dimopoulos, Mohammad Salem, Mariam Grigorian, Helle Bruunsgaard, Kirsten Grønbæk,

First published: 22 April 2022
Letter
Open Access

oa

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model
Peter Müller, Conny K. Baldauf, Tobias R. Haage, Emmanouil Charakopoulos, Martin Böttcher, Vikas Bhuria, Dimitrios Mougiakakos, Burkhart Schraven, Thomas Fischer,

First published: 15 April 2022
Editorial
Open Access

oa

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes
Arjan A. van de Loosdrecht, Inga Mandac Smoljanović,

First published: 24 February 2022
Letter
Open Access

oa

Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome
Alexander Chan, Ying Liu, Sean Devlin, Qi Gao, Jeeyeon Baik, Allison Sigler, Dory Londono, Maria Arcila, Ross Levine, Ahmet Dogan, Yanming Zhang, Mikhail Roshal, Wenbin Xiao,

First published: 03 February 2022
Article
Open Access

oa

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
Ruth Wester, Avinash G. Dinmohamed, Bronno van der Holt, Sonja Zweegman, Monique Minnema, Sandra Croockewit, Mark-David Levin, Eduard Libourel, Esther de Waal, Pieter Sonneveld, Jan Cornelissen, Nicole Blijlevens, Annemiek Broijl,

First published: 27 January 2022
Guideline Article - Evidence based
Open Access

oa

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippé, Barbara Denys, Jeffrey L. Jorgensen, Marie C. Bene, Francis Lacombe, Adriana Plesa, Monica L. Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian Schwarzer, Costa Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-Buske, Francesco Buccisano,

First published: 22 December 2021

Collections: Guidelines
Article
Open Access

oa

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora,

First published: 30 November 2021
Perspective
Open Access

oa

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
Hans C. Hasselbalch, Richard T. Silver,

First published: 18 November 2021

Tools

Follow journal

HemaSphere

Applied Filters

Filters

All HemaSphere Articles

oa

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

oa

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis

oa

UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia

oa

U2AF1^S34/Q157 Variants Detected in cis Arise Sequentially in an MDS Patient With Serial Sequencing Spanning 18 Years

oa

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany

oa

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

oa

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis

oa

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

oa

Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?

oa

Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force

oa

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

oa

The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA

oa

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes

oa

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model

oa

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes

oa

Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome

oa

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

oa

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

oa

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

oa

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Tools

Follow journal

HemaSphere

Applied Filters

Filters

Filter by Keyword

Subject Categories

Publication Date

ACCESS STATUS

Author

Article Category

All HemaSphere Articles

Download PDFs

oa Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

oa High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis

oa UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia

oa U2AF1S34/Q157 Variants Detected in cis Arise Sequentially in an MDS Patient With Serial Sequencing Spanning 18 Years

oa Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany

oa A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

oa Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis

oa Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

oa Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?

oa Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force

oa European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

oa The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA

oa Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes

oa Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model

oa EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes

oa Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome

oa Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

oa Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

oa Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

oa New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

oa

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

oa

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis

oa

UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia

oa

U2AF1^S34/Q157 Variants Detected in cis Arise Sequentially in an MDS Patient With Serial Sequencing Spanning 18 Years

oa

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany

oa

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

oa

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis

oa

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

oa

Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?

oa

Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force

oa

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

oa

The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA

oa

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes

oa

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model

oa

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes

oa

Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome

oa

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

oa

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

oa

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

oa

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms